Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer

Sponsor
Fudan University
Study ID
NCT01322152
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • irinotecan, capecitabine — DRUG
    Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.

Study Details

The objectives of this study are to evaluate the efficacy and tolerability of single-week regimen of irinotecan plus capecitabine in the first-line or second-line treatment of advanced colorectal cancer.

Key Dates

Start date
Mar 31, 2011
Status verified
Jun 2013
Primary completion
May 31, 2013
Completion
Jun 30, 2013

Study Design

Enrollment
52 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: wXELIRI regimen

Primary Outcome Measure

Rate of Diarrhea [ Time Frame: eight weeks ]

Related Studies